Allogene Therapeutics Inc...

NASDAQ: ALLO · Real-Time Price · USD
1.10
0.03 (2.80%)
At close: Aug 15, 2025, 3:59 PM
1.12
1.36%
After-hours: Aug 15, 2025, 07:51 PM EDT

Allogene Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a n/a n/a n/a 22K -44K 22K 22K 30K 47K 49K 86K 61K 51K 49K 44K 38.34M
Cost of Revenue
n/a 3.1M 3.23M 3.21M 3.64M 3.56M 3.48M 3.57M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Gross Profit
n/a -3.1M -3.23M -3.21M -3.64M 22K -44K -3.55M 22K 30K 47K 49K 86K 61K 51K 49K 44K 38.34M
Operating Income
-56.82M -65.19M -60.49M -71.77M -71.43M -69.5M -85.17M -63M -80.54M -99.09M -96.37M -82.49M -76.59M -79.99M -73.89M -77.67M -71.03M -33.2M
Interest Income
n/a 5.52M 3.03M 6.71M 4.99M 5.43M 6.26M 6.21M 3.78M 2.06M 2.76M 1M 315K 492K 186K 393K 624K 511K
Pretax Income
-50.94M -59.73M -59.5M -66.29M -66.36M -65M -89.26M -62.29M -79.23M -99.97M -94.85M -83.15M -74.79M -79.85M -74.87M -78.19M -70.94M -33.02M
Net Income
-50.94M -59.73M -59.94M -66.29M -66.36M -65M -89.62M -62.29M -79.23M -99.97M -94.85M -83.15M -74.79M -79.85M -74.87M -78.19M -70.94M -33.02M
Selling & General & Admin
14.28M 14.99M 15.52M 16.33M 16.09M 17.27M 17.22M 17.04M 18.52M 18.88M 21M 18.9M 19.51M 19.9M 19.96M 19M 18.78M 16.36M
Research & Development
40.16M 50.2M 44.97M 44.71M 50.35M 52.26M 54.66M 45.98M 62.04M 80.24M 75.42M 63.64M 57.17M 60.16M 53.98M 58.72M 52.29M 55.18M
Other Expenses
2.38M n/a n/a 10.73M 4.99M n/a 13.24M -3.57M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
56.82M 65.19M 60.49M 71.77M 71.43M 69.53M 85.13M 59.45M 80.56M 99.12M 96.42M 82.54M 76.68M 80.05M 73.94M 77.72M 71.07M 71.55M
Interest Expense
-268K 150K 81K 100K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
n/a 65.19M 60.49M 71.77M 71.43M 69.53M 85.13M 63.02M 80.56M 99.12M 96.42M 82.54M 76.68M 80.05M 73.94M 77.72M 71.07M 71.55M
Income Tax Expense
n/a n/a 443K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Shares Outstanding (Basic)
218.93M 215.36M 210.57M 209.19M 190.03M 169.13M 168.34M 167.65M 146.8M 144.56M 144.15M 143.66M 143.38M 141.36M 139.17M 137.03M 134.83M 132.16M
Shares Outstanding (Diluted)
218.93M 215.36M 210.57M 209.19M 190.03M 169.13M 168.34M 167.65M 146.8M 144.56M 144.15M 143.66M 143.38M 141.36M 139.17M 137.03M 134.83M 132.16M
EPS (Basic)
-0.23 -0.28 -0.28 -0.32 -0.35 -0.38 -0.51 -0.37 -0.54 -0.68 -0.66 -0.58 -0.52 -0.56 -0.54 -0.57 -0.53 -0.25
EPS (Diluted)
-0.23 -0.28 -0.28 -0.32 -0.35 -0.38 -0.51 -0.37 -0.54 -0.68 -0.66 -0.58 -0.52 -0.56 -0.54 -0.57 -0.53 -0.25
EBITDA
-56.82M -56.48M -56.18M -62.99M -62.8M -61.45M -68.45M -58.72M -76.9M -95.58M -93.31M -78.63M -72.92M -76.3M -69.65M -75.34M -69.06M -31.28M
EBIT
n/a -59.58M -59.41M -66.19M -66.44M -65M -71.86M -62.29M -80.54M -99.09M -96.37M -82.49M -76.59M -79.99M -73.89M -77.67M -71.03M -33.2M
Depreciation & Amortization
n/a 3.1M 3.23M 3.21M 3.64M 3.56M 3.48M 3.57M 3.64M 3.51M 3.07M 3.86M 3.67M 3.69M 4.24M 2.33M 1.96M 1.92M